Actively Recruiting
Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation.
Led by University Hospital, Angers · Updated on 2025-09-24
2224
Participants Needed
10
Research Sites
169 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Patients with hematologic malignancies requiring intensive chemotherapy are at risk for life-threatening complications. Organ failure may appear rapidly and delay in initiating life-sustaining interventions may result in increased mortality. This encourages great alertness although not all patients require close monitoring. It is therefore critical to identify which patients are the most at risk for clinical deterioration to consider increased surveillance in these patients. The benefit of early intensive care unit (ICU) admission, as soon as the first signs of organ dysfunction appear, must also be clarified. Such an intervention could increase survival of patients by close monitoring and early initiation of organ-specific interventions but could also be responsible for anxiety and increased use of ICU resources. Many teams have analyzed the impact of early warning systems (EWS) including vital signs to detect organ dysfunction early on. It has been shown that these EWS could positively impact survival in many medical fields (pre-hospital, medicine or surgery departments). A few retrospective studies have explored the impact of EWS in hematology, with overall good prediction for ICU admission and mortality. Until now, it has however not been formally demonstrated that early ICU admission, as soon as the first signs of organ dysfunction appear, could benefit patients with hematologic malignancies. A randomized controlled trial studying the impact of early intervention would clarify the role of such a strategy. In this study, the investigators will prospectively evaluate the implementation of the National Early Warning Score (NEWS), with systematic referral to the ICU in high-score patients, to improve the survival of patients receiving intensive chemotherapy in ten academic centers. This score is one of the most performant and most frequently used to predict organ failure. Its calculation only requires vital signs such as respiratory rate, peripheral oxygen saturation, need for oxygen therapy, body temperature, arterial pressure, heart rate, and level of consciousness. The investigators will therefore study the impact of ICU admission in patients with high NEWS in a randomized, controlled trial. A cluster randomization is planned in which the centers will be randomized between usual care (control group) and interventional care with transfer to the ICU in the event of a NEWS score ≥7 (interventional group). Each parameter used to calculate the NEWS will be collected at least three times a day by the attending nurse.
CONDITIONS
Official Title
Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patient
- Hospitalized in a protected hematology unit for induction therapy of acute myeloid leukemia, acute lymphoblastic leukemia, intensive chemotherapy with autologous or allogeneic hematopoietic cell transplantation
- Expected hospital stay in hematology department of at least 7 days
- Patient with social security
- Signed informed consent form
You will not qualify if you...
- Decision to limit care with no transfer to ICU or no organ support initiation
- Pregnant, parturient, or breastfeeding woman
- Person deprived of liberty by judicial or administrative decision
- Person under forced psychiatric care
- Person under legal protection
- Person unable to express consent
- Hospitalization for Chimeric Antigenic Receptor (CAR) T-cell therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 10 locations
1
Centre Hospitalier Amiens-Picardie
Amiens, France, 80054
Actively Recruiting
2
Centre Hospitalier Universitaire d'Angers
Angers, France, 49933
Actively Recruiting
3
Centre Hospitalier Universitaire Besancon
Besançon, France, 25030
Actively Recruiting
4
Centre Hospitalier Universitaire Brest
Brest, France, 29609
Actively Recruiting
5
Centre Hospitalier universitaire Nancy
Nancy, France, 45011
Actively Recruiting
6
Centre Hospitalier Universitaire Nantes
Nantes, France, 44093
Actively Recruiting
7
Centre Hospitalier Universitaire poitiers
Poitiers, France, 86021
Actively Recruiting
8
centre Hospitalier Universitaire Saint etienne
Saint-Etienne, France, 42270
Actively Recruiting
9
centre Hospitalier Universitaire Strasbourg
Strasbourg, France, 67098
Not Yet Recruiting
10
centre Hospitalier Universitaire Tours
Tours, France, 37044
Actively Recruiting
Research Team
C
Corentin Orvain, MD PhD
CONTACT
A
Aurélie Hautefort
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here